SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2012 / Cilt: 12 - Sayı: 7

Ötiroid hastalarda düşük serum FT3 düzeyleri koroner arter hastalığının varlığı ve şiddeti ile ilişkilidir: Gözlemsel bir çalışma

Low serum free triiodothyronine levels are associated with the presence and severity of coronary artery disease in the euthyroid patients: An observational study

Hasan KAYA
Faruk ERTAŞ
Mehmet Serdar SOYDİNÇ
Pages
591–596
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: FT3 levels were significantly lower in subjects with CAD (4.0±0.7 vs. 4.6±0.6 pmol/L; p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to investigate the relationship between serum thyroid hormone levels that are within the normal range and the presence and severity of coronary artery disease (CAD) in patients referred for coronary angiography.
📊
Key Findings & Data:Methods: In this observational study, we enrolled 119 consecutive patients (77 men, mean age 60.7±13.8 years) who underwent coronary angiography.
💡
Conclusion & Impact:Results: FT3 levels were significantly lower in subjects with CAD (4.0±0.7 vs. 4.6±0.6 pmol/L; p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study is to investigate the relationship between serum thyroid hormone levels that are within the normal range and the presence and severity of coronary artery disease (CAD) in patients referred for coronary angiography. Methods: In this observational study, we enrolled 119 consecutive patients (77 men, mean age 60.7±13.8 years) who underwent coronary angiography. Blood samples were tested for thyroid stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4) concentrations. Additionally, risk factors, clinical characteristics and angiographic results were obtained. The patients were separated into two groups according to the Gensini score as those with mild or severe atherosclerosis. Statistical analysis was performed using the Chi-square, Mann-Whitney U, correlation and logistic regression tests, and ROC analysis. Results: FT3 levels were significantly lower in subjects with CAD (4.0±0.7 vs. 4.6±0.6 pmol/L; p

Özet

Amaç: Çalışmamızın amacı, koroner anjiyografi için kaynak gösterilen hastalarda normal sınırlardaki tiroid hormon düzeylerinin koroner arter hastalığının (KAH) varlığı ve şiddeti ile ilişkisini araştırmaktır. Yöntem: Bu gözlemsel çalışmaya koroner anjiyografi yapılan ardışık 119 hasta (77 erkek, ortalama yaş 60.7±13.8 yıl) alındı. Serum serbest triiyodotironin (FT3), serbest tiroksin (FT4) ve tiroid uyarıcı hormon (TSH) düzeyleri alınan kan örneklerinde test edildi. Hastaların konvansiyonel risk faktörleri, klinik karakteristikleri ve anjiyografi sonuçları değerlendirildi. Hastalar Gensini skoruna göre hafif ve şiddetli ateroskleroz olarak iki ayrı gruba ayrıldı. İstatistiksel analiz olarak Ki-kare, Mann-Whitney U testleri ve korelasyon, lojistik regresyon ve ROC analizleri kullanıldı. Bulgular: Serum FT3 düzeyleri KAHı olan kişilerde olmayanlara oranla önemli ölçüde düşük bulundu (4.0±0.7 karşı 4.6±0.6 pmol/L; p

🔖

Cite This Article

KAYA, H., ERTAŞ, F., SOYDİNÇ, M. S. (2022). Ötiroid hastalarda düşük serum FT3 düzeyleri koroner arter hastalığının varlığı ve şiddeti ile ilişkilidir: Gözlemsel bir çalışma. Anadolu Kardiyoloji Dergisi, Cilt: 12 - Sayı: 7, 591–596. https://ajindex.com/articles/436403

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-9
  2. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation 1993;87:1435-41
  3. Roffi M, Cattaneo F, Brandle M. Thyrotoxicosis and the cardiovascular system. Minerva Endocrinol 2005; 30: 47-58
  4. Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992; 327: 94-8
  5. Biondi B, Klein I. Hypothyroidism as a risk factor for cardiovascular disease. Endocrine 2004; 24: 1-13
  6. Cappola AR, Ladenson PW Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003; 88: 2438-44
  7. Tatar E, Kircelli F, Asci G, Carrero JJ, Gungor O, Demirci MS, et al. Associations of triiodothyronine levels with carotid atherosclerosis and arterial stiffness in hemodialysis patients. Clin J Am Soc Nephrol 2011; 9: 2240-6
  8. Peters A, Ehlers M, Blank B, Exler D, Falk C, Kohlmann T, et al. Excess triiodothyronine as a risk factor of coronary events. Arch Intern Med 2000; 13: 1993-9
  9. Bergeron GA, Goldsmith R, Schiller NB. Myocardial infarction, severe reversible ischemia, and shock following excess thyroid administration in a woman with normal coronary arteries. Arch Intern Med 1988; 148: 1450-3
  10. Auer J, Berent R, Weber T, Lassnig E, Eber B. Thyroid function is associated with presence and severity of coronary atherosclerosis. Clin Cardiol 2003; 12: 569-73
  11. Yun KH, Jeong MH, Oh SK, Lee EM, Lee J, Rhee SJ. Relationship of thyroid stimulating hormone with coronary atherosclerosis in angina patients. Int J Cardiol 2007; 122: 56-60
  12. Judkins MP. Selective coronary arteriography.I. A percutaneous transfemoral technique. Radiology 1967; 89:815-24
  13. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606
  14. Oishi Y, Wakatsuki T, Nishikado A. Circulating adhesion molecules and severity of coronary atherosclerosis. Coron Artery Dis 2000; 11:77-81
  15. Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. Endocr Rev 2011; 32: 670-93
  16. Berker D, Işık S, Canbay A, Aydın Y, Tutuncu Y, Delibaşı T, et al. Comparison of antithyroid drugs efficacy on P wave changes in patients with Graves' disease. Anadolu Kardiyol Derg 2009; 9: 298-303
  17. Ishikawa T, Chijiwa T, Hagiwara M, Mamiya S, Hidaka H. Thyroid hormones directly interact with vascular smooth muscle strips. Mol Pharmacol 1989; 6: 760-5
  18. Mamiya S, Hagi